Lester J - Search Results

1

The use of bisphosphonates in breast cancer.

Lester J, Coleman R. Lester J, et al. J Br Menopause Soc. 2005 Mar;11(1):12-7. doi: 10.1258/1362180053654501. J Br Menopause Soc. 2005. PMID: 15814057 Review.

2

Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.

Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit OP, McCloskey E, Coleman RE. Brown JE, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5406-10. doi: 10.1158/1078-0432.CCR-07-0247. Clin Cancer Res. 2007. PMID: 17875770 Clinical Trial.

3

Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE. Lester JE, et al. Clin Cancer Res. 2008 Oct 1;14(19):6336-42. doi: 10.1158/1078-0432.CCR-07-5101. Clin Cancer Res. 2008. PMID: 18829518 Clinical Trial.

4

Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom.

Lester JE, Dodwell D, Horsman JM, Mori S, Coleman RE. Lester JE, et al. Br J Cancer. 2006 Jan 16;94(1):30-5. doi: 10.1038/sj.bjc.6602892. Br J Cancer. 2006. PMID: 16317429 Free PMC article.

5

Bone loss and the aromatase inhibitors.

Lester J, Coleman R. Lester J, et al. Br J Cancer. 2005 Aug;93 Suppl 1(Suppl 1):S16-22. doi: 10.1038/sj.bjc.6602691. Br J Cancer. 2005. PMID: 16100521 Free PMC article. Review.

6

The causes and treatment of bone loss associated with carcinoma of the breast.

Lester J, Dodwell D, McCloskey E, Coleman R. Lester J, et al. Cancer Treat Rev. 2005 Apr;31(2):115-42. doi: 10.1016/j.ctrv.2005.01.008. Cancer Treat Rev. 2005. PMID: 15847981 Review.

7

Zoledronic acid.

Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E, Brown J. Coleman R, et al. Among authors: lester j. Expert Opin Drug Saf. 2011 Jan;10(1):133-45. doi: 10.1517/14740338.2011.540387. Epub 2010 Nov 29. Expert Opin Drug Saf. 2011. PMID: 21114419 Review.

8

The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases.

Lester JE, Brown JE, Hannon RA, Ellis SP, Horsman JM, Purohit OP, Coleman RE. Lester JE, et al. Bone. 2010 Mar;46(3):801-5. doi: 10.1016/j.bone.2009.11.016. Epub 2009 Nov 18. Bone. 2010. PMID: 19931437

9

Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial.

Lester JE, Dodwell D, Brown JE, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Coleman RE. Lester JE, et al. J Bone Oncol. 2012 Jul 11;1(2):57-62. doi: 10.1016/j.jbo.2012.06.002. eCollection 2012 Sep. J Bone Oncol. 2012. PMID: 26909256 Free PMC article.

10

RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.

Gupta A, Roberts C, Tysoe F, Goff M, Nobes J, Lester J, Marshall E, Corner C, Wolstenholme V, Kelly C, Wise A, Collins L, Love S, Woodward M, Salisbury A, Middleton MR. Gupta A, et al. Among authors: lester j. Br J Cancer. 2016 Nov 8;115(10):1193-1200. doi: 10.1038/bjc.2016.318. Epub 2016 Oct 6. Br J Cancer. 2016. PMID: 27711083 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

742 results

Search Page

Filters